APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncolytic Virus Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oncolytic Virus Service Market Outlook and Growth Opportunities 2026

2 May 2026193 pages

Choose your research edition.

Industry ResearchOncolytic Virus Service Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncolytic Virus Service Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Oncolytic Virus Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncolytic Virus Service Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncolytic Virus Service Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Oncolytic Virus Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oncolytic Virus Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oncolytic Virus Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oncolytic Virus Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oncolytic Virus Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oncolytic Virus Service market include Creative Biolabs, Creative Biogene, Recipharm, Nabios, IDT Biologika, FUJIFILM Diosynth Biotechnologies, Exothera, Lonza and ABL, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Oncolytic Virus Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oncolytic Virus Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oncolytic Virus Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oncolytic Virus Service market.

Oncolytic Virus Service Segment by Company

Creative Biolabs

Creative Biogene

Recipharm

Nabios

IDT Biologika

FUJIFILM Diosynth Biotechnologies

Exothera

Lonza

ABL

Takara Bio

Libentech

Oncolytic Virus Service Segment by Type

Measles Virus (MeV)

Herpes Simplex Virus (HSV-1)

Others

Oncolytic Virus Service Segment by Application

Tumor Treatment

Scientific Research

Oncolytic Virus Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oncolytic Virus Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oncolytic Virus Service key companies, revenue, market share, and recent developments.

3. To split the Oncolytic Virus Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oncolytic Virus Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oncolytic Virus Service significant trends, drivers, influence factors in global and regions.

6. To analyze Oncolytic Virus Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oncolytic Virus Service industry.

Chapter 3: Detailed analysis of Oncolytic Virus Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oncolytic Virus Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oncolytic Virus Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oncolytic Virus Service Industry Trends Table 2. Oncolytic Virus Service Industry Drivers Table 3. Oncolytic Virus Service Industry Opportunities and Challenges Table 4. Oncolytic Virus Service Industry Restraints Table 5. Global Oncolytic Virus Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oncolytic Virus Service Revenue Share by Company (2021-2026) Table 7. Global Oncolytic Virus Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oncolytic Virus Service Key Company Manufacturing Base & Headquarters Table 9. Global Oncolytic Virus Service Company, Product Type & Application Table 10. Global Oncolytic Virus Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oncolytic Virus Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Measles Virus (MeV) Table 15. Significant Companies of Herpes Simplex Virus (HSV-1) Table 16. Significant Companies of Others Table 17. Global Oncolytic Virus Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Oncolytic Virus Service Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Oncolytic Virus Service Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Oncolytic Virus Service Sales Value Share by Type (2021-2026) Table 21. Global Oncolytic Virus Service Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Tumor Treatment Table 23. Significant Companies of Scientific Research Table 24. Global Oncolytic Virus Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Oncolytic Virus Service Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Oncolytic Virus Service Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Oncolytic Virus Service Sales Value Share by Application (2021-2026) Table 28. Global Oncolytic Virus Service Sales Value Share by Application (2027-2032) Table 29. Global Oncolytic Virus Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Oncolytic Virus Service Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Oncolytic Virus Service Sales Value Share by Region (2021-2026) Table 32. Global Oncolytic Virus Service Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Oncolytic Virus Service Sales Value Share by Region (2027-2032) Table 34. Global Oncolytic Virus Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Oncolytic Virus Service Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Oncolytic Virus Service Sales Value Market Share by Country (2021-2026) Table 37. Global Oncolytic Virus Service Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Oncolytic Virus Service Sales Value Market Share by Country (2027-2032) Table 39. Creative Biolabs Company Information Table 40. Creative Biolabs Business Overview Table 41. Creative Biolabs Oncolytic Virus Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Creative Biolabs Oncolytic Virus Service Product Portfolio Table 43. Creative Biolabs Recent Development Table 44. Creative Biogene Company Information Table 45. Creative Biogene Business Overview Table 46. Creative Biogene Oncolytic Virus Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Creative Biogene Oncolytic Virus Service Product Portfolio Table 48. Creative Biogene Recent Development Table 49. Recipharm Company Information Table 50. Recipharm Business Overview Table 51. Recipharm Oncolytic Virus Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Recipharm Oncolytic Virus Service Product Portfolio Table 53. Recipharm Recent Development Table 54. Nabios Company Information Table 55. Nabios Business Overview Table 56. Nabios Oncolytic Virus Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Nabios Oncolytic Virus Service Product Portfolio Table 58. Nabios Recent Development Table 59. IDT Biologika Company Information Table 60. IDT Biologika Business Overview Table 61. IDT Biologika Oncolytic Virus Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. IDT Biologika Oncolytic Virus Service Product Portfolio Table 63. IDT Biologika Recent Development Table 64. FUJIFILM Diosynth Biotechnologies Company Information Table 65. FUJIFILM Diosynth Biotechnologies Business Overview Table 66. FUJIFILM Diosynth Biotechnologies Oncolytic Virus Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. FUJIFILM Diosynth Biotechnologies Oncolytic Virus Service Product Portfolio Table 68. FUJIFILM Diosynth Biotechnologies Recent Development Table 69. Exothera Company Information Table 70. Exothera Business Overview Table 71. Exothera Oncolytic Virus Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Exothera Oncolytic Virus Service Product Portfolio Table 73. Exothera Recent Development Table 74. Lonza Company Information Table 75. Lonza Business Overview Table 76. Lonza Oncolytic Virus Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Lonza Oncolytic Virus Service Product Portfolio Table 78. Lonza Recent Development Table 79. ABL Company Information Table 80. ABL Business Overview Table 81. ABL Oncolytic Virus Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. ABL Oncolytic Virus Service Product Portfolio Table 83. ABL Recent Development Table 84. Takara Bio Company Information Table 85. Takara Bio Business Overview Table 86. Takara Bio Oncolytic Virus Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Takara Bio Oncolytic Virus Service Product Portfolio Table 88. Takara Bio Recent Development Table 89. Libentech Company Information Table 90. Libentech Business Overview Table 91. Libentech Oncolytic Virus Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Libentech Oncolytic Virus Service Product Portfolio Table 93. Libentech Recent Development Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Oncolytic Virus Service Product Image Figure 2. Global Oncolytic Virus Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncolytic Virus Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Oncolytic Virus Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Measles Virus (MeV) Image Figure 8. Herpes Simplex Virus (HSV-1) Image Figure 9. Others Image Figure 10. Global Oncolytic Virus Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Oncolytic Virus Service Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Oncolytic Virus Service Sales Value Share by Type (2021-2032) Figure 13. Tumor Treatment Image Figure 14. Scientific Research Image Figure 15. Global Oncolytic Virus Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Oncolytic Virus Service Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Oncolytic Virus Service Sales Value Share by Application (2021-2032) Figure 18. Global Oncolytic Virus Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Oncolytic Virus Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Oncolytic Virus Service Sales Value (2021-2032) & (US$ Million) Figure 21. North America Oncolytic Virus Service Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Oncolytic Virus Service Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Oncolytic Virus Service Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Oncolytic Virus Service Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Oncolytic Virus Service Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Oncolytic Virus Service Sales Value (2021-2032) & (US$ Million) Figure 27. South America Oncolytic Virus Service Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Oncolytic Virus Service Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Oncolytic Virus Service Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Oncolytic Virus Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Measles Virus (MeV)
  • Herpes Simplex Virus (HSV-1)
  • Others
Applications
  • Tumor Treatment
  • Scientific Research
Companies covered
  • Creative Biolabs
  • Creative Biogene
  • Recipharm
  • Nabios
  • IDT Biologika
  • FUJIFILM Diosynth Biotechnologies
  • Exothera
  • Lonza
  • ABL
  • Takara Bio
  • Libentech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oncolytic Virus Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oncolytic Virus Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oncolytic Virus Service Market Dynamics
  1. 2.1 Oncolytic Virus Service Industry Trends
  2. 2.2 Oncolytic Virus Service Industry Drivers
  3. 2.3 Oncolytic Virus Service Industry Opportunities and Challenges
  4. 2.4 Oncolytic Virus Service Industry Restraints
3 Oncolytic Virus Service Market by Company
  1. 3.1 Global Oncolytic Virus Service Company Revenue Ranking in 2025
  2. 3.2 Global Oncolytic Virus Service Revenue by Company (2021-2026)
  3. 3.3 Global Oncolytic Virus Service Company Ranking (2024-2026)
  4. 3.4 Global Oncolytic Virus Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Oncolytic Virus Service Company Product Type and Application
  6. 3.6 Global Oncolytic Virus Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oncolytic Virus Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oncolytic Virus Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oncolytic Virus Service Market by Type
  1. 4.1 Oncolytic Virus Service Type Introduction
  2. 4.1.1 Measles Virus (MeV)
  3. 4.1.2 Herpes Simplex Virus (HSV-1)
  4. 4.1.3 Others
  5. 4.2 Global Oncolytic Virus Service Sales Value by Type
  6. 4.2.1 Global Oncolytic Virus Service Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Oncolytic Virus Service Sales Value by Type (2021-2032)
  8. 4.2.3 Global Oncolytic Virus Service Sales Value Share by Type (2021-2032)
5 Oncolytic Virus Service Market by Application
  1. 5.1 Oncolytic Virus Service Application Introduction
  2. 5.1.1 Tumor Treatment
  3. 5.1.2 Scientific Research
  4. 5.2 Global Oncolytic Virus Service Sales Value by Application
  5. 5.2.1 Global Oncolytic Virus Service Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Oncolytic Virus Service Sales Value by Application (2021-2032)
  7. 5.2.3 Global Oncolytic Virus Service Sales Value Share by Application (2021-2032)
6 Oncolytic Virus Service Regional Value Analysis
  1. 6.1 Global Oncolytic Virus Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oncolytic Virus Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oncolytic Virus Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oncolytic Virus Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oncolytic Virus Service Sales Value (2021-2032)
  7. 6.3.2 North America Oncolytic Virus Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oncolytic Virus Service Sales Value (2021-2032)
  10. 6.4.2 Europe Oncolytic Virus Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oncolytic Virus Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oncolytic Virus Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oncolytic Virus Service Sales Value (2021-2032)
  16. 6.6.2 South America Oncolytic Virus Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oncolytic Virus Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oncolytic Virus Service Sales Value Share by Country, 2025 VS 2032
7 Oncolytic Virus Service Country-level Value Analysis
  1. 7.1 Global Oncolytic Virus Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oncolytic Virus Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oncolytic Virus Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oncolytic Virus Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oncolytic Virus Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oncolytic Virus Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oncolytic Virus Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Creative Biolabs
  2. 8.1.1 Creative Biolabs Company Information
  3. 8.1.2 Creative Biolabs Business Overview
  4. 8.1.3 Creative Biolabs Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Creative Biolabs Oncolytic Virus Service Product Portfolio
  6. 8.1.5 Creative Biolabs Recent Developments
  7. 8.2 Creative Biogene
  8. 8.2.1 Creative Biogene Company Information
  9. 8.2.2 Creative Biogene Business Overview
  10. 8.2.3 Creative Biogene Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Creative Biogene Oncolytic Virus Service Product Portfolio
  12. 8.2.5 Creative Biogene Recent Developments
  13. 8.3 Recipharm
  14. 8.3.1 Recipharm Company Information
  15. 8.3.2 Recipharm Business Overview
  16. 8.3.3 Recipharm Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Recipharm Oncolytic Virus Service Product Portfolio
  18. 8.3.5 Recipharm Recent Developments
  19. 8.4 Nabios
  20. 8.4.1 Nabios Company Information
  21. 8.4.2 Nabios Business Overview
  22. 8.4.3 Nabios Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Nabios Oncolytic Virus Service Product Portfolio
  24. 8.4.5 Nabios Recent Developments
  25. 8.5 IDT Biologika
  26. 8.5.1 IDT Biologika Company Information
  27. 8.5.2 IDT Biologika Business Overview
  28. 8.5.3 IDT Biologika Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 IDT Biologika Oncolytic Virus Service Product Portfolio
  30. 8.5.5 IDT Biologika Recent Developments
  31. 8.6 FUJIFILM Diosynth Biotechnologies
  32. 8.6.1 FUJIFILM Diosynth Biotechnologies Company Information
  33. 8.6.2 FUJIFILM Diosynth Biotechnologies Business Overview
  34. 8.6.3 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 FUJIFILM Diosynth Biotechnologies Oncolytic Virus Service Product Portfolio
  36. 8.6.5 FUJIFILM Diosynth Biotechnologies Recent Developments
  37. 8.7 Exothera
  38. 8.7.1 Exothera Company Information
  39. 8.7.2 Exothera Business Overview
  40. 8.7.3 Exothera Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Exothera Oncolytic Virus Service Product Portfolio
  42. 8.7.5 Exothera Recent Developments
  43. 8.8 Lonza
  44. 8.8.1 Lonza Company Information
  45. 8.8.2 Lonza Business Overview
  46. 8.8.3 Lonza Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lonza Oncolytic Virus Service Product Portfolio
  48. 8.8.5 Lonza Recent Developments
  49. 8.9 ABL
  50. 8.9.1 ABL Company Information
  51. 8.9.2 ABL Business Overview
  52. 8.9.3 ABL Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ABL Oncolytic Virus Service Product Portfolio
  54. 8.9.5 ABL Recent Developments
  55. 8.10 Takara Bio
  56. 8.10.1 Takara Bio Company Information
  57. 8.10.2 Takara Bio Business Overview
  58. 8.10.3 Takara Bio Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Takara Bio Oncolytic Virus Service Product Portfolio
  60. 8.10.5 Takara Bio Recent Developments
  61. 8.11 Libentech
  62. 8.11.1 Libentech Company Information
  63. 8.11.2 Libentech Business Overview
  64. 8.11.3 Libentech Oncolytic Virus Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Libentech Oncolytic Virus Service Product Portfolio
  66. 8.11.5 Libentech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst